Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.
Linde MH, Fan AC, Köhnke T, Trotman-Grant AC, Gurev SF, Phan P, Zhao F, Haddock NL, Nuno KA, Gars EJ, Stafford M, Marshall PL, Dove CG, Linde IL, Landberg N, Miller LP, Majzner RG, Zhang TY, Majeti R. Linde MH, et al. Cancer Discov. 2023 May 4;13(5):1164-1185. doi: 10.1158/2159-8290.CD-21-0502. Cancer Discov. 2023. PMID: 36856575
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL. Majzner RG, et al. Among authors: linde mh. Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17. Clin Cancer Res. 2019. PMID: 30655315 Free PMC article.
Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection.
Marshall PL, Nagy N, Kaber G, Barlow GL, Ramesh A, Xie BJ, Linde MH, Haddock NL, Lester CA, Tran QL, de Vries CR, Hargil A, Malkovskiy AV, Gurevich I, Martinez HA, Kuipers HF, Yadava K, Zhang X, Evanko SP, Gebe JA, Wang X, Vernon RB, de la Motte C, Wight TN, Engleman EG, Krams SM, Meyer EH, Bollyky PL. Marshall PL, et al. Among authors: linde mh. Matrix Biol. 2021 Feb;96:69-86. doi: 10.1016/j.matbio.2020.12.001. Epub 2020 Dec 5. Matrix Biol. 2021. PMID: 33290836 Free PMC article.
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A, Lattin J, Xu P, Huang J, Nasholm N, He A, Kuo TC, Sangalang ERB, Pons J, Barkal A, Brewer RE, Marjon KD, Vilches-Moure JG, Marshall PL, Fernandes R, Monje M, Cochran JR, Sorensen PH, Daldrup-Link HE, Weissman IL, Sage J, Majeti R, Bertozzi CR, Weiss WA, Mackall CL, Majzner RG. Theruvath J, et al. Among authors: linde mh. Nat Med. 2022 Feb;28(2):333-344. doi: 10.1038/s41591-021-01625-x. Epub 2022 Jan 13. Nat Med. 2022. PMID: 35027753 Free PMC article.
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, Majeti R, Satpathy AT, Stegmaier K, Majzner RG. Mabe NW, et al. Among authors: linde mh. Nat Cancer. 2022 Aug;3(8):976-993. doi: 10.1038/s43018-022-00405-x. Epub 2022 Jul 11. Nat Cancer. 2022. PMID: 35817829 Free PMC article.
Neutrophil-activating therapy for the treatment of cancer.
Linde IL, Prestwood TR, Qiu J, Pilarowski G, Linde MH, Zhang X, Shen L, Reticker-Flynn NE, Chiu DK, Sheu LY, Van Deursen S, Tolentino LL, Song WC, Engleman EG. Linde IL, et al. Among authors: linde mh. Cancer Cell. 2023 Feb 13;41(2):356-372.e10. doi: 10.1016/j.ccell.2023.01.002. Epub 2023 Jan 26. Cancer Cell. 2023. PMID: 36706760 Free PMC article.
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.
Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE, Linde IL, Guerrero M, Veatch JR, Snyder AG, Welm AL, Riddell SR, Ghajar CM. Goddard ET, et al. Among authors: linde mh. Cancer Cell. 2024 Jan 8;42(1):119-134.e12. doi: 10.1016/j.ccell.2023.12.011. Cancer Cell. 2024. PMID: 38194912
13 results